Motilal Oswal Alternate Investment Advisors plans to invest up to Rs 460 crore for a majority stake in Mumbai-based Megafine Pharma, an API manufacturer with USFDA-approved facilities in Nashik and Vapi. The Sanghvi family, founding promoters, are also increasing their stake. Megafine specializes in high-value, low-volume active pharmaceutical ingredients, and offers contract manufacturing services. With the API industry in India experiencing growth due to outsourcing and supply chain shifts, the investment aims to enhance Megafine’s R&D and manufacturing capabilities, as well as explore further inorganic opportunities for growth.